All Stories

  1. Liquid Chromatography-Tandem Mass Spectrometry Method for Ticagrelor and its Active Metabolite Determination in Human Plasma: Application to a Pharmacokinetic Study

    Article • Current Analytical Chemistry, July 2020, Bentham Science Publishers

    Niloufar Marsousi, Youssef Daali

  2. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes

    Article • Basic & Clinical Pharmacology & Toxicology, October 2018, Wiley

    Youssef Daali

  3. Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software

    Article • Biopharmaceutics & Drug Disposition, November 2017, Wiley

    Youssef Daali

  4. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions

    Article • Clinical Pharmacology & Therapeutics, November 2017, Wiley

    Youssef Daali

  5. Why Has Model-Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future

    Article • Clinical Pharmacology & Therapeutics, April 2017, Wiley

    Youssef Daali

  6. Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study

    Article • Pharmacological Research, April 2017, Elsevier

    Youssef Daali

  7. Prioritization of Active Pharmaceutical Ingredients in Hospital Wastewater

    Article • January 2017, Springer Science + Business Media

    Youssef Daali

  8. Plasma concentrations of transdermal fentanyl and buprenorphine in pigs ( Sus scrofa domesticus )

    Article • Veterinary Anaesthesia and Analgesia, January 2017, Elsevier

    Youssef Daali

  9. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect

    Article • Frontiers in Pharmacology, December 2016, Frontiers

    Youssef Daali

  10. Hepatocyte Concentrations of Indocyanine Green Reflect Transfer Rates Across Membrane Transporters

    Article • Basic & Clinical Pharmacology & Toxicology, November 2016, Wiley

    Youssef Daali

  11. Detection of busulfan adducts on proteins

    Article • Rapid Communications in Mass Spectrometry, October 2016, Wiley

    Youssef Daali

  12. Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases

    Article • Journal of Pharmaceutical and Biomedical Analysis, September 2016, Elsevier

    Youssef Daali

  13. Intestinal permeability and P-glycoprotein-mediated efflux transport of ticagrelor in Caco-2 monolayer cells

    Article • Fundamental and Clinical Pharmacology, August 2016, Wiley

    Youssef Daali

  14. Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach

    Article • Clinical Pharmacology & Therapeutics, July 2016, Wiley

    Youssef Daali, Niloufar Marsousi

  15. An extensive cocktail approach for rapid risk assessment of in vitro CYP450 direct reversible inhibition by xenobiotic exposure

    Article • Toxicology and Applied Pharmacology, July 2016, Elsevier

    Youssef Daali

  16. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method

    Article • Basic & Clinical Pharmacology & Toxicology, April 2016, Wiley

    Youssef Daali

  17. Pharmacogenomics of Oral Antithrombotic Drugs

    Article • Current Pharmaceutical Design, April 2016, Bentham Science Publishers

    Youssef Daali

  18. Dynamics of active pharmaceutical ingredients loads in a Swiss university hospital wastewaters and prediction of the related environmental risk for the aquatic ecosystems

    Article • The Science of The Total Environment, March 2016, Elsevier

    Youssef Daali

  19. Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study

    Article • Clinical Therapeutics, January 2016, Elsevier

    Youssef Daali

  20. Development of an LC-MS/MS Method for the Assessment of Selected Active Pharmaceuticals and Metabolites in Wastewaters of a Swiss University Hospital

    Article • CHIMIA International Journal for Chemistry, November 2015, Swiss Chemical Society

    Youssef Daali

  21. Prioritization methodology for the monitoring of active pharmaceutical ingredients in hospital effluents

    Article • Journal of Environmental Management, September 2015, Elsevier

    Youssef Daali

  22. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies

    Article • Platelets, August 2015, Informa Healthcare

    Youssef Daali

  23. Vincristine-Induced Neuropathic Pain In A Cyp3a5 Non-Expresser With Reduced Cyp3a4 Activity

    Article • Clinical Therapeutics, August 2015, Elsevier

    Youssef Daali

  24. In-vitro evaluation of DDI with cobicistat and ritonavir using heparg cell line

    Article • Clinical Therapeutics, August 2015, Elsevier

    Youssef Daali

  25. Innovative approach to Blood sampling using dried Blood spots. application to Pharmacokinetics and Cytochrome P450 Phenotyping

    Article • Clinical Therapeutics, August 2015, Elsevier

    Youssef Daali

  26. Evaluation of CYP450 and transporters expression and activity in heparg cell line under different conditions

    Article • Clinical Therapeutics, August 2015, Elsevier

    Youssef Daali

  27. Screening for phenotypical variation in CYP activity in patients with therapeutic problem in psychiatric settings

    Article • Clinical Therapeutics, August 2015, Elsevier

    Youssef Daali

  28. Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review

    Article • Current Drug Metabolism, July 2015, Bentham Science Publishers

    Youssef Daali

  29. Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription

    Article • Current Drug Metabolism, July 2015, Bentham Science Publishers

    Youssef Daali

  30. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study

    Article • International Journal of Antimicrobial Agents, April 2015, Elsevier

    Youssef Daali

  31. GABAergic modulation in central sensitization in humans

    Article • Pain, March 2015, Wolters Kluwer Health

    Youssef Daali

  32. Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model

    Article • CPT Pharmacometrics & Systems Pharmacology, December 2014, Wiley

    Youssef Daali

  33. A cocktail approach for assessing the in vitro activity of human cytochrome P450s: An overview of current methodologies

    Article • Journal of Pharmaceutical and Biomedical Analysis, December 2014, Elsevier

    Youssef Daali

  34. Phenotyping of CYP450 in human liver microsomes using the cocktail approach

    Article • Analytical and Bioanalytical Chemistry, June 2014, Springer Science + Business Media

    Youssef Daali

  35. Incorporation of Flurbiprofen in a 4-Drug Cytochrome P450 Phenotyping Cocktail

    Article • Basic & Clinical Pharmacology & Toxicology, April 2014, Wiley

    Youssef Daali

  36. Geneva Cocktail for Cytochrome P450 and P-Glycoprotein Activity Assessment Using Dried Blood Spots

    Article • Clinical Pharmacology & Therapeutics, April 2014, Nature

    Youssef Daali

  37. Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review

    Article • Current Drug Metabolism, April 2014, Bentham Science Publishers

    Youssef Daali

  38. Role of paraoxonase-1 in CYP2C19 loss-of-function carriers

    Article • Thrombosis Research, March 2014, Elsevier

    Youssef Daali

  39. Simultaneous LC–MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma

    Article • Bioanalysis, January 2014, Future Science

    Youssef Daali

  40. Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity

    Article • AIDS Research and Therapy, January 2014, Springer Science + Business Media

    Youssef Daali

  41. Antiplatelet Therapy: Targeting the TxA2 Pathway

    Article • Journal of Cardiovascular Translational Research, December 2013, Springer Science + Business Media

    Youssef Daali

  42. Real‐time monitoring of exhaled drugs by mass spectrometry

    Article • Mass Spectrometry Reviews, November 2013, Wiley

    Renato Zenobi, Youssef Daali

  43. Intérêt des outils d’investigation des enzymes métaboliques en pratique clinique

    Article • Douleur et Analgésie, November 2013, Springer Science + Business Media

    Youssef Daali

  44. Utilisation des analgésiques dans l’insuffisance hépatique

    Article • Douleur et Analgésie, November 2013, Springer Science + Business Media

    Youssef Daali

  45. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation

    Article • The Pharmacogenomics Journal, October 2013, Nature

    Youssef Daali

  46. Influence des polymorphismes génétiques sur la variabilité de la réponse aux opioïdes

    Article • Douleur et Analgésie, October 2013, Springer Science + Business Media

    Youssef Daali

  47. PP233—CYP1A activity after chronic exposure to dioxins from a waste incinerator

    Article • Clinical Therapeutics, August 2013, Elsevier

    Youssef Daali

  48. PP175—Evidence of Drug–Drug Interactions Through Uptake and Efflux Transport Systems in Rat Hepatocytes: Implications For Cellular Concentrations Of Competing Drugs

    Article • Clinical Therapeutics, August 2013, Elsevier

    Youssef Daali

  49. Molecular Imaging Reveals Rapid Reduction of Endothelial Activation in Early Atherosclerosis With Apocynin Independent of Antioxidative Properties

    Article • Arteriosclerosis Thrombosis and Vascular Biology, August 2013, Wolters Kluwer Health

    Youssef Daali

  50. PP121—CYP2C9 genotypes associated with higher sulfolane levels in children receiving intravenous busulfan prior to hematopoietic stem cell transplantation

    Article • Clinical Therapeutics, August 2013, Elsevier

    Youssef Daali

  51. Oc027—Dual Reuptake Inhibitor Milnacipran And Spinal Pain Pathways In Fibromyalgia Patients: A Randomized Double-Blind Placebo-Controlled Trial

    Article • Clinical Therapeutics, August 2013, Elsevier

    Youssef Daali

  52. PP134—Esomeprazole used as a booster in a HIV ultrarapid CYP2C19 metabolizer treated with voriconazole

    Article • Clinical Therapeutics, August 2013, Elsevier

    Youssef Daali

  53. PP193—Simultaneous LC-MS/MS Quantification of P-Glycoprotein and Cytochrome P450 Probe Substrates and Their Metabolites In Dried Blood Spots

    Article • Clinical Therapeutics, August 2013, Elsevier

    Youssef Daali

  54. PP189—A Physiologically-Based Mechanistic Pharmacokinetic Model to Assess the Metabolism of Oxycodone in Healthy Volunteers: Interplay Between CYP3A and 2D6 Inhibition

    Article • Clinical Therapeutics, August 2013, Elsevier

    Youssef Daali

  55. PP129—Time-to-achieve stability of anticoagulation is decreased in ABCB1 mutated patients treated with acenocoumarol

    Article • Clinical Therapeutics, August 2013, Elsevier

    Youssef Daali

  56. Evidence of Drug-Drug Interactions through Uptake and Efflux Transport Systems in Rat Hepatocytes: Implications for Cellular Concentrations of Competing Drugs

    Article • Drug Metabolism and Disposition, May 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Youssef Daali

  57. Applications of CYP450 Testing in the Clinical Setting

    Article • Molecular Diagnosis & Therapy, April 2013, Springer Science + Business Media

    Youssef Daali

  58. Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model

    Article • Journal of Antimicrobial Chemotherapy, March 2013, Oxford University Press (OUP)

    Youssef Daali

  59. Antihyperalgesic Effect of the GABAALigand Clobazam in a Neuropathic Pain Model in Mice: A Pharmacokinetic-Pharmacodynamic Study

    Article • Basic & Clinical Pharmacology & Toxicology, November 2012, Wiley

    Youssef Daali

  60. Serotonin syndrome following drug–drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient

    Article • AIDS, November 2012, Wolters Kluwer Health

    Youssef Daali

  61. Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers

    Article • Basic & Clinical Pharmacology & Toxicology, October 2012, Wiley

    Youssef Daali

  62. Transcriptional Regulation of CYP2C19 and its Role in Altered Enzyme Activity

    Article • Current Drug Metabolism, September 2012, Bentham Science Publishers

    Youssef Daali

  63. NADPH Oxidase NOX2 Defines a New Antagonistic Role for Reactive Oxygen Species and cAMP/PKA in the Regulation of Insulin Secretion

    Article • Diabetes, August 2012, American Diabetes Association

    Youssef Daali

  64. Analgesics in Patients with Hepatic Impairment

    Article • Drugs, August 2012, Springer Science + Business Media

    Youssef Daali

  65. The paraoxonase‐1 pathway is not a major bioactivation pathway of clopidogrel in vitro

    Article • British Journal of Pharmacology, July 2012, Wiley

    Youssef Daali

  66. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis

    Article • Journal of Thrombosis and Haemostasis, July 2012, Wiley

    Youssef Daali

  67. Validation of the Simplified UVB Model to Assess the Pharmacodynamics of Analgesics in Healthy Human Volunteers

    Article • CHIMIA International Journal for Chemistry, May 2012, Swiss Chemical Society

    Youssef Daali

  68. A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry

    Article • Rapid Communications in Mass Spectrometry, May 2012, Wiley

    Youssef Daali

  69. Oral Flurbiprofen Metabolic Ratio Assessment Using a Single-Point Dried Blood Spot

    Article • Clinical Pharmacology & Therapeutics, January 2012, Nature

    Youssef Daali

  70. Pharmacokinetic-Pharmacodynamic Modelling of Opioids in Healthy Human Volunteers. A MiniReview

    Article • Basic & Clinical Pharmacology & Toxicology, November 2011, Wiley

    Youssef Daali

  71. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug–drug interaction in HIV patients

    Article • Metabolism, November 2011, Elsevier

    Youssef Daali

  72. A Randomized, Controlled Trial Validates a Peripheral Supra-Additive Antihyperalgesic Effect of a Paracetamol-Ketorolac Combination

    Article • Basic & Clinical Pharmacology & Toxicology, July 2011, Wiley

    Youssef Daali

  73. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain

    Article • Neuropharmacology, March 2011, Elsevier

    Youssef Daali

  74. Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite

    Article • Journal of Pharmaceutical and Biomedical Analysis, January 2011, Elsevier

    Youssef Daali

  75. How Organic Anions Accumulate in Hepatocytes Lacking Mrp2: Evidence in Rat Liver

    Article • Journal of Pharmacology and Experimental Therapeutics, December 2010, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Youssef Daali

  76. Two structurally different T-type Ca2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats

    Article • Fundamental and Clinical Pharmacology, October 2010, Wiley

    Youssef Daali

  77. Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability

    Article • Current Drug Metabolism, October 2010, Bentham Science Publishers

    Youssef Daali

  78. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone

    Article • British Journal of Pharmacology, May 2010, Wiley

    Youssef Daali

  79. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety

    Article • British Journal of Pharmacology, March 2010, Wiley

    Youssef Daali

  80. On-line desorption of dried blood spots coupled to hydrophilic interaction/reversed-phase LC/MS/MS system for the simultaneous analysis of drugs and their polar metabolites

    Article • Journal of Separation Science, March 2010, Wiley

    Youssef Daali

  81. P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone

    Article • Fundamental and Clinical Pharmacology, October 2009, Wiley

    Youssef Daali

  82. Uptake/Efflux Transport of Tramadol Enantiomers andO-Desmethyl-Tramadol: Focus onP-Glycoprotein

    Article • Basic & Clinical Pharmacology & Toxicology, September 2009, Wiley

    Youssef Daali

  83. Two-dimensional liquid chromatography–ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma

    Article • Journal of Chromatography A, May 2009, Elsevier

    Youssef Daali

  84. Métastase vésiculaire d’un cancer du rein

    Article • Gastroentérologie Clinique et Biologique, August 2008, Elsevier

    Youssef Daali

  85. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

    Article • The Pharmacogenomics Journal, July 2008, Nature

    Youssef Daali

  86. Influence of ABCB1 Gene Polymorphisms and P-Glycoprotein Activity on Cyclosporine Pharmacokinetics in Peripheral Blood Mononuclear Cells in Healthy Volunteers

    Article • Drug Metabolism Letters, April 2008, Bentham Science Publishers

    Youssef Daali

  87. Lack of Interaction of the NMDA Receptor Antagonists Dextromethorphan and Dextrorphan with P-Glycoprotein

    Article • Current Drug Metabolism, February 2008, Bentham Science Publishers

    Youssef Daali

  88. Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: Application to the assessment of CYP2D6 activity in fibromyalgia patients

    Article • Journal of Chromatography B, January 2008, Elsevier

    Youssef Daali

  89. Pharmacokinetic and Pharmacodynamic Properties of Buprenorphine After a Single Intravenous Administration in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study

    Article • Clinical Therapeutics, August 2007, Elsevier

    Youssef Daali

  90. 420 SIGNIFICANCE OF GENETIC AND NEUROPHYSIOLOGICAL ASPECTS IN FIBROMYALGIA

    Article • European Journal of Pain, September 2006, Wiley

    Youssef Daali

  91. 653 DIFFERENTIAL TRANSPORT OF OPIOIDS, NMDA ANTAGONIST AND THEIR ACTIVE METABOLITES MAY INFLUENCE THEIR ANALGESIC EFFICACY

    Article • European Journal of Pain, September 2006, Wiley

    Youssef Daali

  92. PIII-1Determinant role of CYP2D6 and CYP3A4 pathways on the antinociceptive effects of oxycodone

    Article • Clinical Pharmacology & Therapeutics, February 2006, Nature

    Youssef Daali

  93. PIII-2Lack of tramadol and its active metabolite O-desmethyl-tramadol interaction with P-glycoprotein

    Article • Clinical Pharmacology & Therapeutics, February 2006, Nature

    Youssef Daali

  94. Development and validation of a new reversed-phase ion pairing liquid chromatographic method with fluorescence detection for penciclovir analysis in plasma and aqueous humor

    Article • Journal of Chromatography B, November 2005, Elsevier

    Youssef Daali

  95. Not all statins interfere with clopidogrel during antiplatelet therapy

    Article • European Journal of Clinical Investigation, August 2005, Wiley

    Youssef Daali

  96. Lack of dextromethorphan interaction with P-glycoprotein

    Article • Clinical Pharmacology & Therapeutics, February 2005, Nature

    Youssef Daali

  97. Assessment of naltrexone antagonism of buprenorphine

    Article • Clinical Pharmacology & Therapeutics, February 2005, Nature

    Youssef Daali

  98. Pharmacokinetics and analgesic effects of intravenous buprenorphine

    Article • Clinical Pharmacology & Therapeutics, February 2005, Nature

    Youssef Daali

  99. Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism

    Article • New England Journal of Medicine, December 2004, New England Journal of Medicine (NEJM/MMS)

    Youssef Daali

  100. A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes

    Article • Journal of Pharmaceutical and Biomedical Analysis, September 2004, Elsevier

    Youssef Daali

  101. High performance liquid chromatography of acarbose and its metabolite on porous graphitic carbon column

    Article • Journal of Separation Science, April 2002, Wiley

    Youssef Daali

  102. Simultaneous analysis of polyhydroxylated alkaloids by capillary electrophoresis using borate complexation and evaluation of sweeping technique for sensitivity improvement

    Article • Chromatographia, February 2002, Springer Science + Business Media

    Youssef Daali

  103. Calystegine distribution in some solanaceous species

    Article • Phytochemistry, October 2001, Elsevier

    Youssef Daali

  104. Routine o-glycan characterization in nutritional supplements — a comparison of analytical methods for the monitoring of the bovine kappa-casein macropeptide glycosylation

    Article • Journal of Chromatography A, September 2001, Elsevier

    Youssef Daali

  105. Capillary electrophoresis and high-performance anion exchange chromatography for monitoring caseinoglycomacropeptide sialylation

    Article • Journal of Pharmaceutical and Biomedical Analysis, March 2001, Elsevier

    Youssef Daali

  106. Use of borate complexation for the separation of non-UV-absorbing calystegines by capillary electrophoresis

    Article • Journal of Chromatography A, December 2000, Elsevier

    Youssef Daali

  107. Partial Solubility Parameters of Lactose, Mannitol and Saccharose Using the Modified Extended Hansen Method and Evaporation Light Scattering Detection.

    Article • Chemical and Pharmaceutical Bulletin, January 2000, Pharmaceutical Society of Japan

    Youssef Daali

  108. Experimental design for enantioselective separation of celiprolol by capillary electrophoresis using sulfated β-cyclodextrin

    Article • Electrophoresis, November 1999, Wiley

    Youssef Daali

  109. Experimental design for enantioselective separation of celiprolol by capillary electrophoresis using sulfated β-cyclodextrin

    Article • Electrophoresis, November 1999, Wiley

    Youssef Daali

  110. Development and validation of liquid chromatography and capillary electrophoresis methods for acarbose determination in pharmaceutical tablets

    Article • Journal of Pharmaceutical and Biomedical Analysis, December 1998, Elsevier

    Youssef Daali